WillItSurvive
Pharma and healthcare groups · subsidiary of Piramal Group (Ajay Piramal family) · India

Piramal Pharma

piramalpharma.com ↗

Indian CDMO plus hospital generics and consumer health company with $1B+ revenue and 17 GMP plants.

Defensible for now
Assessed 26 July 2026 · Evidence as of 26 July 2026
Real protection, with named pressure against it.
On the recordSince 26 July 2026 · Checkable from 30 July 2026 · Every call on the record Checkpoint: Q1FY27 earnings report on whether destocking clears and CDMO RFPs convert to revenue
The call

A physically-anchored CDMO and generics business riding out a cyclical dip, with the FDA inspection outcome and next quarter's order conversion set to show whether the recovery story holds.

Piramal Pharma makes medicines for other companies in its factories, sells generic pills to hospitals, and sells health products to consumers. It is hard to replace because it has 17 FDA-approved factories, long-term contracts with big customers, and years of regulatory paperwork already done. China-based WuXi AppTec used to be a threat, but US rules are pushing that work toward Piramal instead. The real question is whether Piramal grows faster than Indian rivals like Divi's and Syngene when the medicine-making business picks back up. If Piramal does not beat these competitors, then it is just one more factory in a crowded field.

Why
01
AI pressure: None apparent. AI can speed drug discovery elsewhere but does not replace GMP manufacturing capacity or FDA approvals Piramal already holds. Could AI do the core job? Unlikely.
02
Bigger players: Lonza and Samsung Biologics. Bigger, better-funded CDMOs are also expanding capacity to catch the same China-plus-one reshoring demand. Could a giant copy it? Probably.
03
What protects it. FDA-approved plants and per-molecule switching costs make customers slow to move production once qualified.
What would change this call
Q1FY27 earnings (due ~30 Jul 2026) show CDMO revenue growth resuming or still declining. Tests whether the FY26 dip was cyclical destocking or a structural loss of orders.
FDA inspection outcome at Sellersville facility (inspected 9 Jul 2026). A warning letter or serious Form 483 would show regulatory risk hitting CDMO capacity.
Piramal's CDMO revenue growth rate versus Divi's, Syngene, Suven and Laurus over the next 2-3 quarters. Shows whether Piramal is gaining or losing share within the CDMO peer group.
Key numbers
  • FY2026 revenue fell 3% YoY to Rs 8,869 crore (2026-03-31)
  • FY2026 net loss of Rs 325.94 crore (2026-03-31)
  • CDMO segment (PPS) made up 55% of revenue (2026-03-31)
Named risks
  • FDA inspection outcome at Sellersville (inspected July 9, 2026) could yield warning letter or 483 observations. Severity: high
  • FY2026 revenue decline (-3%) and net loss may extend into FY2027 if destocking does not clear. Severity: medium
  • Ahmedabad facility operations suspended due to heavy rainfall as of July 24, 2026, resumption timeline unclear. Severity: medium
  • Crowded Indian CDMO peer field (Divi's, Syngene, Suven, Laurus) competing for same China+1 demand pool. Severity: medium
  • HDFC Mutual Fund reduced stake by ~2.0% around July 18, 2026, signaling institutional caution. Severity: low
Rivals, as read in July 2026
RivalDirectionEvidence
WuXi AppTec/WuXi Biologicsgaining onPiramal positioned to absorb CDMO demand as China-based WuXi retreats under US Biosecure Act pressure, mid-2026
Divi's LaboratoriescontestingDivi's FY26 net profit up 17% to Rs 2,568 crore, exports 89% of sales, competing for same China+1 demand
Syngene InternationalcontestingGoldman Sachs also rates Syngene Buy with Rs 525 target as rival CRDMO pick, July 8, 2026
Suven PharmaceuticalscontestingSuven targets $1B revenue by 2030 as product-led CDMO rival, per May 2025 coverage
Laurus LabscontestingLaurus CDMO small-molecule division grew 49% in FY25, outpacing Piramal's FY26 decline
Bristol-Myers Squibb (customer/peer)losing toBMS announced major AI-infrastructure initiative with NVIDIA July 20, 2026; Piramal has no disclosed equivalent
Questions people ask
Is Piramal Pharma profitable in 2026?
No. Piramal Pharma reported a one-off net loss of Rs 325.94 crore for FY2026 (ended March 31, 2026), driven by destocking of a large CDMO product and injectable supply constraints, versus a 5x YoY profit jump in FY2025 when revenue topped $1 billion.
Could AI replace Piramal Pharma's CDMO business?
Unlikely for core work. Piramal's revenue depends on regulated GMP sterile manufacturing, fill-finish, and ADC conjugation across 17 physical facilities with FDA inspection track records, not software. AI may speed early discovery chemistry, but physical scale-up and regulatory approvals remain the moat as of July 2026.
Who is Piramal Pharma's biggest competitor?
Piramal competes with Indian CDMO peers Divi's Laboratories, Syngene International, Suven Pharmaceuticals, and Laurus Labs, all chasing China+1 supply-chain diversification demand. Globally, WuXi AppTec and WuXi Biologics are the China-based incumbents losing share under US Biosecure Act pressure, as of mid-2026.
Who owns Piramal Pharma?
Piramal Pharma Limited (NSE: PPLPHARMA) is publicly listed, part of the Piramal Group led by the Ajay Piramal family, with Nandini Piramal as Chairperson and Peter DeYoung as CEO. It demerged from Piramal Enterprises and listed on NSE/BSE in August 2022, per Wikipedia (June 2026).
Why did Piramal Pharma's revenue decline in FY2026?
Piramal Pharma's FY2026 consolidated revenue fell about 3% YoY to Rs 8,869 crore, which management called a 'transitional year' caused by destocking of a large commercial CDMO product and supply constraints in injectable pain management, per its April 28, 2026 results announcement.
Does Piramal Pharma face FDA inspection risk?
Yes. The US FDA inspected Piramal's Sellersville facility on July 9, 2026, with results pending as of the July 24, 2026 disclosure. Piramal reported 30 inspections cleared including 2 US FDA inspections without major observations in the prior quarter (as of January 29, 2026).
Timeline
  • 2026-07-24Piramal suspends Ahmedabad facility operations due to heavy rainfall, files SEBI disclosure
  • 2026-07-09US FDA inspects Piramal's Sellersville facility
  • 2026-07-07FY2026 annual report discloses 17 facilities, 7,285 employees, $90M sterile/ADC capacity commitment
  • 2026-04-30Kenalog acquisition from Bristol-Myers Squibb closes
  • 2026-04-28FY2026 results: revenue down ~3% to Rs 8,869 crore, net loss of Rs 325.94 crore
  • 2026-01-31Piramal Critical Care agrees to acquire Kenalog brand from BMS for up to $100M
  • 2026-01-29Q3FY26 earnings call cites 30 inspections cleared including 2 FDA inspections with no major observations
  • 2025-09-16Korsch XM-12 bilayer tablet press added at Morpeth, UK facility
  • 2025-09-01CDMO RFP inflows and biopharma funding begin improving, per management commentary
  • 2025-08-01Piramal Pharma lists on NSE/BSE following demerger (referenced as 2022 listing in later filings)
Revision history
26 July 2026
First assessed. Defensible for now. The text above is fixed as of this date and is not edited afterwards.
In the same band
ZoetisBoston ScientificBecton Dickinson
More in Pharma and healthcare groups →
Sources